London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Hikma’s CEO, said: “I am pleased ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Verapamil comes as a tablet, an extended-release (long-acting) tablet, and an extended-release (long-acting) capsule. The dose prescribed for preventing migraines varies from 120 milligrams (mg) to ...

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials".

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.